Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ThisCART19A is an allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen. Developed by The First Affiliated Hospital of Soochow University, it is specifically designed for the treatment of relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). Unlike traditional autologous CAR-T therapies that use a patient's own cells, ThisCART19A utilizes donor-derived (allogeneic) T cells. It is currently being evaluated in clinical trials as a bridge therapy to hematopoietic stem cell transplantation (HSCT), aiming to achieve remission and stabilize patients before they undergo a transplant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ThisCART19A (First Affiliated Hospital of Soochow University).